Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY

Belén Ruiz-Antorán, Aránzazu Sancho-López, Ferran Torres, Víctor Moreno-Torres Concha, Itziar de Pablo López de Abechuco, Paulina García López, Francisco Abad-Santos, Clara María Rosso Fernández, Ana Aldea-Perona, Eva Montané, Ruth M. Aparicio-Hdez, Roser LLop Rius, Consuelo Pedrós, Paloma Gijón, Carolina Hernández Carballo, María José Pedrosa Martínez, Consuelo Rodríguez Jiménez, Guillermo Prada-Ramallal, Lourdes Cabrera García, Josefa Andrea Aguilar García, Rocío Sanjuan-Jimenez, Evelyn Iveth Ortiz Barraza, Enrique Sánchez-Chica, Ana Fernández-Cruz on behalf of the TOCICOV-study group
doi: https://doi.org/10.1101/2020.09.07.20189357
Belén Ruiz-Antorán
1Clinical Pharmacology Department. Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aránzazu Sancho-López
1Clinical Pharmacology Department. Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferran Torres
2Medical Statistics Core Facility, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic, Barcelona; Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Víctor Moreno-Torres Concha
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Itziar de Pablo López de Abechuco
4Clinical Pharmacology Unit. Hospital Universitario Ramón y Cajal (IRYCIS). Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulina García López
5Pneumology Department, Hospital Universitario Torrecardenas, Almería, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Abad-Santos
6Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara María Rosso Fernández
7Unit of Clinical Pharmacology, Unit of Clinical Investigation and Clinical Trials, Hospital Universitario Virgen del Rocío, Sevilla, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Aldea-Perona
8Clinical Pharmacology Department. Consorcio Parc Salut Mar. Instituto Hospital del Mar de Investigaciones Médicas (IMIM). Universidad Autónoma de Barcelona (UAB), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Montané
9Clinical Pharmacology Department, Hospital Universitario Germans Trias i Pujol; Department of Pharmacology, Therapeutics and Toxicology, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth M. Aparicio-Hdez
10Clinical Pharmacology Department, Hospital Universitario Central de la Defensa Gómez Ulla, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roser LLop Rius
11Clinical Pharmacology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Consuelo Pedrós
12Clinical Pharmacology Unit, Consorci Hospital General Universitari de València, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paloma Gijón
13Clinical Microbiology and Infectious Diseases Department. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Hernández Carballo
14Internal Medicine Department. Hospital Universitario Nuestra Señora Candelaria, Tenerife, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María José Pedrosa Martínez
15Clinical Pharmacology Department, Hospital Universitario Puerto Real, Cádiz, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Consuelo Rodríguez Jiménez
16Clinical Pharmacology Department. Hospital Universitario de Canarias. Tenerife, España; Departamento de Medicina Física y Farmacología, Facultad de Medicina, Universidad de La Laguna (ULL), Tenerife, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo Prada-Ramallal
17Epidemiology, Statistics and Research Methodology Unit. Institute for Health Research Foundation (FIDIS). Santiago de Compostela, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lourdes Cabrera García
18Clinical Pharmacology Department. Hospital Universitario Clínico San Carlos, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefa Andrea Aguilar García
19Internal Medicine Department. Hospital Costa del Sol Marbella, Málaga, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rocío Sanjuan-Jimenez
20UICEC IBIMA, Plataforma SCReN; Servicio de Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Málaga, España
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelyn Iveth Ortiz Barraza
21Internal Medicine Department. Hospital Universitario Ramón y Cajal (IRYCIS). Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Sánchez-Chica
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Fernández-Cruz
22Infectious Diseases Unit. Internal Medicine Department. Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anafcruz999@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background We aimed to determine the impact of tocilizumab use in severe COVID-19 pneumonia mortality.

Methods We performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain, from March to April 2020. Consecutive patients admitted with severe COVID-19 treated with tocilizumab were compared to patients not treated with tocilizumab, adjusting by Inverse Probability of the Treatment Weights (IPTW). Tocilizumab effect in patients receiving steroids during the 48h following inclusion was analyzed.

Results During the study period, 506 patients with severe COVID-19 fulfilled inclusion criteria. Among them, 268 were treated with tocilizumab and 238 patients were not. Median time to tocilizumab treatment from onset of symptoms was 11 days (IQR 8-14). Global mortality was 23.7%. Mortality was lower in patients treated with tocilizumab than in controls (16.8% versus 31.5%, HR 0.514 [95CI 0.355-0.744], p< 0.001; weighted HR 0.741 [95CI 0.619-0.887], p = 0.001). Tocilizumab treatment reduced mortality by 14.7% relative to no tocilizumab treatment (RRR 46.7%). We calculated a number necessary to treat of 7. Among patients treated with steroids, mortality was lower in patients treated with tocilizumab than in those treated with steroids alone (10.9% versus 40.2%, HR 0.511 [95CI 0.352-0.741], p = 0.036; weighted HR 0.6 [95CI 0.449-0.804], p< 0.001) (Interaction p = 0.094).

Conclusions These results show that survival of patients with severe COVID-19 is higher in patients treated with tocilizumab than in those not treated, and that tocilizumab effect adds to that of steroids administered to non-intubated cases with COVID-19 during the first 48 hours of presenting with respiratory failure despite of oxygen therapy. Randomised controlled studies are needed to confirm these results.

Summary We investigated in-hospital mortality of patients with severe SARS-CoV-2 pneumonia in a multicenter series of patients treated with tocilizumab compared to controls, and adjusted using IPTW. Our results show a beneficial impact of tocilizumab treatment in SARS-CoV-2 pneumonia, that adds to that of steroids.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Registration: The protocol of the study was registered in EU PAS Register #EUPAS34415 on 31th March 2020 and publicly available at: http://www.encepp.eu/encepp/viewResource.htm?id=35237

Clinical Protocols

http://www.encepp.eu/encepp/viewResource.htm?id=35237

Funding Statement

No funding was received for this article.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by Spanish Agency for Medicine and Health Product and by the Institutional Review Board (CEIm) at Hospital Universitario Puerta de Hierro-Majadahonda (FIB-TOC-2020-01), and a waiver for the informed consent was granted. The study complied with the provisions in European Union (EU) and Spanish legislation on data protection and the Declaration of Helsinki 2013.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data sharing: After publication, the data will be made available to others on reasonable requests to the corresponding authors. A proposal with a detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. De-identified participant data will be provided after approval from the principal researchers of the Hospital Puerta de Hierro-Majadahonda.

  • ABBREVIATIONS

    95CI
    95% confidence interval
    COPD
    chronic obstructive pulmonary disease
    COVID-19
    coronavirus disease 2019
    CoV
    coronavirus
    CRP
    C- reactive protein
    CT
    computed tomography
    HR
    hazard ratio
    ICU
    Intensive care Unit
    IL-6
    interleukin-6
    IPTW
    inverse probability treatment weighting
    IQR
    interquartile range
    LDH
    Lactate dehydrogenase
    PaO2/FiO2
    arterial oxygen tension/inspiratory oxygen fraction
    DD
    D-dimer
    RRR
    relative risk reduction
    SARS-CoV
    severe acute respiratory syndrome coronavirus
    SD
    standard deviation
    SGOT/AST
    aspartate aminotransferase
    SaO2
    arterial oxygen saturation
    Steroids
    glucocorticoids or corticoids
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted September 10, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY
    Belén Ruiz-Antorán, Aránzazu Sancho-López, Ferran Torres, Víctor Moreno-Torres Concha, Itziar de Pablo López de Abechuco, Paulina García López, Francisco Abad-Santos, Clara María Rosso Fernández, Ana Aldea-Perona, Eva Montané, Ruth M. Aparicio-Hdez, Roser LLop Rius, Consuelo Pedrós, Paloma Gijón, Carolina Hernández Carballo, María José Pedrosa Martínez, Consuelo Rodríguez Jiménez, Guillermo Prada-Ramallal, Lourdes Cabrera García, Josefa Andrea Aguilar García, Rocío Sanjuan-Jimenez, Evelyn Iveth Ortiz Barraza, Enrique Sánchez-Chica, Ana Fernández-Cruz
    medRxiv 2020.09.07.20189357; doi: https://doi.org/10.1101/2020.09.07.20189357
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY
    Belén Ruiz-Antorán, Aránzazu Sancho-López, Ferran Torres, Víctor Moreno-Torres Concha, Itziar de Pablo López de Abechuco, Paulina García López, Francisco Abad-Santos, Clara María Rosso Fernández, Ana Aldea-Perona, Eva Montané, Ruth M. Aparicio-Hdez, Roser LLop Rius, Consuelo Pedrós, Paloma Gijón, Carolina Hernández Carballo, María José Pedrosa Martínez, Consuelo Rodríguez Jiménez, Guillermo Prada-Ramallal, Lourdes Cabrera García, Josefa Andrea Aguilar García, Rocío Sanjuan-Jimenez, Evelyn Iveth Ortiz Barraza, Enrique Sánchez-Chica, Ana Fernández-Cruz
    medRxiv 2020.09.07.20189357; doi: https://doi.org/10.1101/2020.09.07.20189357

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (243)
    • Allergy and Immunology (524)
    • Anesthesia (125)
    • Cardiovascular Medicine (1430)
    • Dentistry and Oral Medicine (219)
    • Dermatology (158)
    • Emergency Medicine (292)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (588)
    • Epidemiology (10321)
    • Forensic Medicine (6)
    • Gastroenterology (532)
    • Genetic and Genomic Medicine (2649)
    • Geriatric Medicine (255)
    • Health Economics (499)
    • Health Informatics (1744)
    • Health Policy (791)
    • Health Systems and Quality Improvement (679)
    • Hematology (269)
    • HIV/AIDS (569)
    • Infectious Diseases (except HIV/AIDS) (12112)
    • Intensive Care and Critical Care Medicine (649)
    • Medical Education (274)
    • Medical Ethics (83)
    • Nephrology (291)
    • Neurology (2476)
    • Nursing (145)
    • Nutrition (381)
    • Obstetrics and Gynecology (496)
    • Occupational and Environmental Health (569)
    • Oncology (1330)
    • Ophthalmology (403)
    • Orthopedics (151)
    • Otolaryngology (238)
    • Pain Medicine (172)
    • Palliative Medicine (51)
    • Pathology (343)
    • Pediatrics (784)
    • Pharmacology and Therapeutics (334)
    • Primary Care Research (296)
    • Psychiatry and Clinical Psychology (2415)
    • Public and Global Health (5025)
    • Radiology and Imaging (898)
    • Rehabilitation Medicine and Physical Therapy (532)
    • Respiratory Medicine (686)
    • Rheumatology (309)
    • Sexual and Reproductive Health (257)
    • Sports Medicine (246)
    • Surgery (299)
    • Toxicology (45)
    • Transplantation (141)
    • Urology (108)